| Eli Lilly and Company | |||||||||||||||||
| Operating Results (Unaudited) – Non-GAAP | |||||||||||||||||
| (Dollars in millions, except per share data) | |||||||||||||||||
Three Months Ended | Six Months Ended | ||||||||||||||||
June 30 | June 30 | ||||||||||||||||
2010(a) | 2009(b) | % Chg. | 2010(a) | 2009(b) | % Chg. | ||||||||||||
| Total Revenue | 5,748.7 | 5,292.8 | 9% | 11,234.2 | 10,339.8 | 9% | |||||||||||
| Cost of sales | 1,023.9 | 947.4 | 8% | 2,146.4 | 1,763.8 | 22% | |||||||||||
| Research and development | 1,187.2 | 1,040.4 | 14% | 2,226.3 | 1,987.7 | 12% | |||||||||||
| Marketing, selling and administrative | 1,755.4 | 1,708.2 | 3% | 3,369.8 | 3,237.4 | 4% | |||||||||||
| Operating income | 1,782.2 | 1,596.8 | 12% | 3,491.7 | 3,350.9 | 4% | |||||||||||
| Net interest income (expense) | (36.5) | (45.5) | (73.5) | (105.7) | |||||||||||||
| Net other income (expense) | 18.1 | 21.4 | 129.6 | 10.9 | |||||||||||||
| Other income (expense) | (18.4) | (24.1) | (24)% | 56.1 | (94.8) | NM | |||||||||||
| Income before income taxes | 1,763.8 | 1,572.7 | 12% | 3,547.8 | 3,256.1 | 9% | |||||||||||
| Income taxes | 396.9 | 346.0 | 15% | 883.3 | 716.3 | 23% | |||||||||||
| Net income | $ | 1,366.9 | $ | 1,226.7 | 11% | $ | 2,664.5 | $ | 2,539.8 | 5% | |||||||
| Earnings per share – basic | $ | 1.24 | $ | 1.12 | 11% | $ | 2.41 | $ | 2.31 | 4% | |||||||
| Earnings per share – diluted | $ | 1.24 | $ | 1.12 | 11% | $ | 2.41 | $ | 2.31 | 4% | |||||||
| Dividends paid per share | $ | .49 | $ | .49 | 0% | $ | .98 | $ | .98 | 0% | |||||||
| Weighted-average shares outstanding (thousands) – basic | 1,103,782 | 1,097,184 | 1,103,817 | 1,097,195 | |||||||||||||
| Weighted-average shares outstanding (thousands) – diluted | 1,103,807 | 1,097,213 | 1,103,843 | 1,097,226 | |||||||||||||
| NM – not meaningful (a) The second-quarter 2010 financial statements have been adjusted to eliminate restructuring charges of $27.3 million (pretax), or $0.02 (after-tax). The year-to-date 2010 financial statements have been adjusted to eliminate total restructuring charges of $53.5 million (pretax), or $0.03 (after-tax). These charges are primarily related to severance costs from previously announced strategic actions that the company is taking to reduce its cost structure and global workforce. In addition, the year-to-date 2010 financial statements have been adjusted to eliminate a charge of $50.0 million (pretax), or $0.03 per share (after-tax), for acquired in-process research and development associated with the in-licensing agreement with Acrux Ltd. (b) The second quarter and year-to-date 2009 financial statements have been adjusted to eliminate a special pretax charge of $105.0 million, or $0.06 per share (after-tax), in connection with several states' litigation claims involving Zyprexa. | |||||||||||||||||
